Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi will pay Kymera Therapeutics $150 million up front in a deal that could be worth more than $2 billion if all milestones are met for rights to develop…
France's Sanofi has signed a deal worth up to about $2 billion to develop drugs for immune-inflammatory diseases with U.S. biotech firm Kymera Therapeutics,…
Kymera Therapeutics reported Phase 1 healthy volunteer data showing that lead IRAK4 protein degrader KT-474 achieved greater than 95 percent IRAK4 knockdown…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Sanofi and Kymera entered a strategic partnership giving Sanofi global rights to Kymera's IRAK4 protein degrader program for immune-inflammatory diseases plus a second undisclosed program. Kymera received $150M cash upfront and is eligible for $2B+ in development, regulatory and sales milestones plus significant royalties. Kymera advanced IRAK4 through Phase 1 before Sanofi assumed clinical development.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Kymera Therapeutics, Inc. (this deal) | 2020 | $2.1B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2020 deals · Sanofi SA deals · Dermatology deals